Section 4: Clinical Pharmacy Services

4CPS-091

CURRENT STATE OF RETREATMENT OF HEPATITIS C INFECTION IN PATIENTS WHOM PRIOR THERAPY FAILED IN A HEPATITIS REFERRAL CENTRE

4CPS-090

HEALTH OUTCOMES USING DIRECT-ACTING ANTIVIRAL DRUGS FOR THE TREATMENT OF PATIENTS WITH HEPATITIS C VIRUS AND F0-F1 LIVER FIBROSIS STAGE

4CPS-089

RETREATMENT OF PATIENTS WITH HEPATITIS C VIRUS INFECTION AFTER VIROLOGICAL FAILURE TO DIRECT-ACTING ANTIVIRALS

4CPS-088

EFFECTIVENESS OF GLECAPREVIR/PIBRENTASVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C

4CPS-087

EVOLUTION OVER TIME OF ANTIRETROVIRALS

4CPS-086

A FULLY INTEGRATED CLINICAL TRIAL-LIKE SYSTEM TO MANAGE AND MONITOR PERSISTENCE IN PLANNED HEPATITIS C TREATMENT

4CPS-085

STEWARDSHIPS OF HEPATITIS C VIRUS PATIENTS IN PRISONS

4CPS-084

EVOLUTION OF NONOCCUPATIONAL POSTEXPOSURE PROPHYLAXIS USE SINCE 2010 IN A THIRD-LEVEL HOSPITAL

4CPS-083

AGING WITH HIV: OPTIMISING PHARMACOTHERAPY BEYOND INTERACTIONS

4CPS-082

NEPHROGENIC DIABETES INSIPIDUS INDUCED BY LIPOSOMAL AMPHOTERICIN B: A CASE REPORT

4CPS-081

EVALUATION OF THE STANDARD DOSAGE REGIMEN OF VORICONAZOLE IN A PAEDIATRIC AND ADULT POPULATION THROUGH THERAPEUTIC DRUG MONITORING

4CPS-080

APPROPRIATE USE OF ANTIFUNGALS: IMPACT OF AN ANTIFUNGAL STEWARDSHIP PROGRAMME ON THE CLINICAL OUTCOME OF CANDIDAEMIA IN A UNIVERSITY HOSPITAL

4CPS-079

PATIENT WITH COMPLICATED FUNGAL ENDOCARDITIS : A CASE REPORT

4CPS-078

ADEQUACY OF SYSTEMATIC ANTIFUNGAL AGENT PRESCRIPTIONS IN A TEACHING HOSPITAL

4CPS-077

INHALED COLISTIN AS CHRONIC SUPPRESSOR THERAPY IN PATIENTS WITH BRONCHIECTASIAS WITH NON-CYSTIC FIBROSIS

Pages